
Annual report 2025
added 02-24-2026
Avanos Medical EBITDA 2011-2026 | AVNS
Earnings before Interest, Taxes, Depreciation, and Amortization (EBITDA), is an often used measure of a company's profitability. Financial analysts use EBITDA for a number of purposes including calculating simple valuations of a firm, estimating cash flows, and assessing debt servicing capability. The uses for EBITDA in financial analysis are numerous, but in practice should be more restrained. While EBITDA has some useful applications, it should be used with caution, as the problems with EBITDA are abundant and can lead to a number of misguided conclusions.[1]
EBITDA is an important indicator for investors and analysts because it allows them to evaluate a company's operating profit without considering the impact of financial expenses, taxes, or non-cash depreciation and amortization. It provides better comparability between companies in different industries or with different tax conditions.
EBITDA is often used to assess a company's ability to generate cash flow and repay debts. It can also serve as a measure of a company's operational efficiency, as it shows how profitable the core business is, regardless of external factors such as interest or taxes.
However, it is important to note that EBITDA is not an official financial statement measure and can be defined and calculated differently by companies. Therefore, investors and analysts should exercise caution when using EBITDA as an evaluation tool and combine it with other financial metrics and information to get a more complete picture of a company's financial condition.
Annual EBITDA Avanos Medical
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -22.7 M | -351 M | 50.3 M | 83.2 M | 48.7 M | -5.6 M | -18.8 M | 34 M | 16.4 M | 153 M | 162 M | 180 M | 294 M | 286 M | 262 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 294 M | -351 M | 78 M |
Quarterly EBITDA Avanos Medical
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 5.1 M | -69.7 M | 19.9 M | - | 17.3 M | 11.3 M | 15.4 M | - | 6 M | 2.4 M | 6 M | - | 17.3 M | 14.5 M | 19.7 M | - | 32.2 M | 11.9 M | -2.7 M | - | 32 M | 19.6 M | 11.2 M | - | 7.5 M | 7.1 M | -16.2 M | - | 31.5 M | 24.4 M | 800 K | - | 38.1 M | 20.3 M | -1.4 M | - | 69.3 M | 49.4 M | 48.7 M | - | -413 M | 54.4 M | 57.3 M | - | 74.7 M | 30.3 M | 79 M | - | 123 M | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 123 M | -413 M | 12.3 M |
References
- Brockman, C. M., & Russell, J. W. (2012). EBITDA: use it... or lose it?. International Journal of Business, Accounting and Finance, 6(2), 84-93.
EBITDA of other stocks in the Medical devices industry
| Issuer | EBITDA | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Viemed Healthcare
VMD
|
51.6 M | $ 9.06 | 1.23 % | $ 347 M | ||
|
Acutus Medical
AFIB
|
-11.5 M | - | -26.83 % | $ 2.62 M | ||
|
Allied Healthcare Products
AHPI
|
-815 K | - | 3.58 % | $ 2.21 M | ||
|
GenMark Diagnostics, Inc.
GNMK
|
-3.98 M | - | - | $ 1.77 B | ||
|
Aziyo Biologics
AZYO
|
-26.8 M | - | 1.37 % | $ 20.5 M | ||
|
Obalon Therapeutics, Inc.
OBLN
|
-9.8 M | - | -5.86 % | $ 30.6 M | ||
|
Bruker Corporation
BRKR
|
437 M | $ 38.78 | -1.25 % | $ 5.78 K | ||
|
Cognyte Software Ltd.
CGNT
|
8.53 M | $ 8.15 | 4.22 % | $ 585 M | ||
|
Conformis
CFMS
|
-42.2 M | - | - | $ 16.4 M | ||
|
AdaptHealth Corp.
AHCO
|
473 M | $ 9.69 | 3.09 % | $ 1.31 B | ||
|
Apollo Endosurgery
APEN
|
-30.2 M | - | - | $ 475 M | ||
|
EDAP TMS S.A.
EDAP
|
-18 M | $ 4.15 | 4.01 % | $ 155 M | ||
|
Cardiovascular Systems
CSII
|
-32.1 M | - | 0.15 % | $ 844 M | ||
|
CONMED Corporation
CNMD
|
120 M | $ 43.13 | -0.43 % | $ 1.34 B | ||
|
Cutera
CUTR
|
-148 M | - | -10.19 % | $ 1.99 M | ||
|
CryoLife, Inc.
CRY
|
23.2 M | - | -4.14 % | $ 702 M | ||
|
Avinger
AVGR
|
-16.3 M | - | -20.74 % | $ 369 K | ||
|
AxoGen
AXGN
|
-1.19 M | $ 29.17 | -2.21 % | $ 1.34 B | ||
|
Apyx Medical Corporation
APYX
|
-16.6 M | $ 3.31 | 4.42 % | $ 115 M | ||
|
Axonics Modulation Technologies
AXNX
|
-53.2 M | - | - | $ 3.31 B | ||
|
Dynatronics Corporation
DYNT
|
-1.97 M | - | 14.99 % | $ 929 K | ||
|
Eargo
EAR
|
-106 M | - | - | $ 10.2 M | ||
|
Electromed
ELMD
|
10.7 M | $ 24.26 | 1.17 % | $ 205 M | ||
|
Soliton, Inc.
SOLY
|
-14.1 M | - | -1.42 % | $ 435 M | ||
|
Hancock Jaffe Laboratories, Inc.
HJLI
|
88.4 K | - | -1.98 % | $ 98.3 M | ||
|
Itamar Medical Ltd.
ITMR
|
-8.53 M | - | 0.03 % | $ 1.58 B | ||
|
Second Sight Medical Products
EYES
|
-24.3 M | - | -0.97 % | $ 54.4 M | ||
|
Accuray Incorporated
ARAY
|
14 M | $ 0.53 | 0.68 % | $ 54.5 M | ||
|
Misonix, Inc.
MSON
|
-15.9 M | - | - | $ 462 M | ||
|
Neovasc
NVCN
|
-31.1 M | - | - | $ 111 M | ||
|
FONAR Corporation
FONR
|
9.84 M | $ 18.51 | 0.05 % | $ 121 M | ||
|
Cytosorbents Corporation
CTSO
|
-15.2 M | $ 0.79 | -1.24 % | $ 43 M | ||
|
Align Technology
ALGN
|
753 M | $ 183.14 | 0.27 % | $ 13.7 B | ||
|
Intersect ENT, Inc.
XENT
|
-64.8 M | - | - | $ 955 M | ||
|
Butterfly Network
BFLY
|
-65.5 M | $ 3.99 | 7.7 % | $ 845 M | ||
|
BIOLASE
BIOL
|
-15.1 M | - | -13.19 % | $ 166 K | ||
|
Abbott Laboratories
ABT
|
9.49 B | $ 113.59 | 0.01 % | $ 198 B | ||
|
InMode Ltd.
INMD
|
86.1 M | $ 13.58 | -0.18 % | $ 878 M | ||
|
BioSig Technologies
BSGM
|
-12.7 M | - | 37.08 % | $ 85.7 M | ||
|
Boston Scientific Corporation
BSX
|
4.98 B | $ 72.75 | -1.49 % | $ 108 B | ||
|
IRadimed Corporation
IRMD
|
22.8 M | $ 105.22 | 0.89 % | $ 1.33 B | ||
|
IRIDEX Corporation
IRIX
|
-8.91 M | $ 1.42 | -0.7 % | $ 22.9 M | ||
|
Helius Medical Technologies
HSDT
|
-12.4 M | $ 2.31 | 16.67 % | $ 1.4 M | ||
|
Alphatec Holdings
ATEC
|
-4.64 M | $ 13.05 | 0.23 % | $ 1.96 B | ||
|
Pulmonx Corporation
LUNG
|
-56.6 M | $ 1.46 | -4.58 % | $ 57.1 M | ||
|
Medigus Ltd.
MDGS
|
-9.9 M | - | 10.28 % | $ 55.5 M | ||
|
Medtronic PLC
MDT
|
8.82 B | $ 95.96 | -0.8 % | $ 123 B | ||
|
Edwards Lifesciences Corporation
EW
|
1.42 B | $ 85.73 | 0.55 % | $ 50.1 B |